REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

neoplasms

The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Alterations in bile acid profile and pathways contribute to hepatic inflammation in cancer cachexia, a syndrome worsening the prognosis of cancer patients. As the gut microbiota impinges on host metabolism through bile acids, the current study aimed to explore the...
๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: Gut Microbes
Read MoreThe microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Body composition alterations in patients with lung cancer.

Most patients with lung cancer experience cancer cachexia (CC), a syndrome of skeletal muscle and adipose tissue wasting. Knowledge of body composition changes in patients is limited, however, because most studies have been cross-sectional, comparing patients with non-cancer controls or...
๐Ÿ—“๏ธ 2025-01-31
๐Ÿ“ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreBody composition alterations in patients with lung cancer.

Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.

Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

The essential amino acid methionine plays a pivotal role in one-carbon metabolism, facilitating the production of S-adenosylmethionine (SAM), a critical supplier for DNA methylation and thereby a modulator of gene expression. Here, we report that the methionine cycle is disrupted...
๐Ÿ—“๏ธ 2024-12-20
๐Ÿ“ฐ Publication: Cell Metabolism
Read MoreDisrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

CT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies.

Older adults with cancer are at an increased risk of treatment related toxicities and early death. Routinely collected clinico-demographic characteristics inadequately explain this increased risk limiting accurate prognostication. Prior studies have suggested that altered body composition and frailty are independently...
๐Ÿ—“๏ธ 2024-12-23
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCT-Based Body Composition and Frailty as Predictors of Survival Among Older Adults With Gastrointestinal Malignancies.

Comment on 'Association of Computed Tomography-Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis' by Van Helsdingen etย al.

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreComment on 'Association of Computed Tomography-Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis' by Van Helsdingen etย al.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...
๐Ÿ—“๏ธ 2024-12-16
Read MoreClinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Targeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles.

Metastatic progression significantly reduces survival rates and complicates treatment strategies in various cancers. Our study introduces an mRNA therapy for metastasis inhibition by targeting activin A overexpression, a pivotal driver of metastasis and cachexia. Utilizing follistatin mRNA lipid nanoparticles, we...
๐Ÿ—“๏ธ 2024-11-21
๐Ÿ“ฐ Publication: Acs Nano
Read MoreTargeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles.

Letter to the Editor-"Risk factors for low muscle mass, malnutrition, and (probable-) sarcopenia in adults with or without a history of cancer in the UK Biobank".

๐Ÿ—“๏ธ 2024-10-10
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreLetter to the Editor-"Risk factors for low muscle mass, malnutrition, and (probable-) sarcopenia in adults with or without a history of cancer in the UK Biobank".

Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.

Leptin is a reliable predictive and surrogate marker of the efficacy of multitargeted treatment of cancer cachexia. To the best of our knowledge, no study has assessed the predictive role of biomarkers in establishing the effectiveness of anti-cachectic treatment, which...
๐Ÿ—“๏ธ 2024-10-10
Read MoreLeptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.

Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable,...
๐Ÿ—“๏ธ 2024-10-22
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBody composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

Impact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

The association between sarcopenia and postoperative complications has been widely reported in patients with cancer. Yet, the lack of standardized population-specific diagnostic cut-off points and assessments of muscle strength is hampering prospective clinical utilization. Therefore, we aimed to examine the...
๐Ÿ—“๏ธ 2024-10-11
Read MoreImpact of sarcopenia and muscle strength on postoperative complication risk following pancreatic resection.

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...
๐Ÿ—“๏ธ 2024-10-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImpact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!